Progress on the development of Class A GPCR‐biased ligands
British Journal of Pharmacology, EarlyView.Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales +20 more
wiley +1 more source
Delusional Infestation Secondary to the Dopamine Agonist Ropirinole in a Patient With Parkinson's Disease: A Case Report With an Outline of the Biology of Psychosis. [PDF]
Cureus, 2021 Kesserwani H.
europepmc +1 more source
A rationale for dopamine agonists as primary therapy for Parkinson's disease.
, 1992 C. Warren Olanow
openalex
(+)‐Dinapsoline: An Efficient Synthesis and Pharmacological Profile of a Novel Dopamine Agonist. [PDF]
, 2002 Sing‐Yuen Sit, NULL AUTHOR_ID
openalex +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson's Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better? [PDF]
Clin Park Relat DisordWu HF +10 more
europepmc +1 more source
Circadian Phase-Dependent Modulation of cGMP-Gated Channels of Cone Photoreceptors by Dopamine and D2 Agonist [PDF]
, 2003 Gladys Y.‐P. Ko +2 more
openalex +1 more source
British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
In Vivo Evidence that 5-HT2C Receptor Antagonist but not Agonist Modulates Cocaine-Induced Dopamine Outflow in the Rat Nucleus Accumbens and Striatum [PDF]
, 2003 Sylvia Navailles +3 more
openalex +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source